Authors’ Reply to Huang and Zhang: Comment on “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”
暂无分享，去创建一个
S. Dai | Shiow-Ing Wang | J. Wei | Q. Tong
[1] Jinxian Huang,et al. Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study” , 2023, Drugs.
[2] S. Dai,et al. Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study , 2022, Drugs.
[3] Md. Mujibur Rahman,et al. 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout , 2021, International journal of rheumatic diseases.
[4] Chih-Cheng Hsu,et al. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout , 2020, Journal of Human Hypertension.
[5] I. Lee,et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan , 2018, International journal of rheumatic diseases.
[6] M. Cravets,et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol , 2016, Annals of the rheumatic diseases.
[7] B. Bajorek,et al. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy , 2014, Pharmacy practice.
[8] Y. Danieli. Guide , 2005 .